OMEROS CORP Long-Term Debt, Maturity, Remainder of Fiscal Year
OMEROS CORP (OMER) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $0 as of 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2025-11-13
- 2025-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2025-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2025-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $10.00M.
- 2023-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $95.00M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 |
| 2025-03-31 | $10.00M 10-Q · filed 2025-05-15 |
| 2023-09-30 | $95.00M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |